Malta - English - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 50 mg - antineoplastic agents

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 200 mg - antineoplastic agents

Malta - English - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 mg/ml - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

seacross pharmaceuticals limited - epirubicin hydrochloride - solution for injection - 2 mg/ml - epirubicin

Ireland - English - HPRA (Health Products Regulatory Authority)

seacross pharma (europe) limited - epirubicin hydrochloride - solution for injection - 2 milligram(s)/millilitre - anthracyclines and related substances; epirubicin

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - epirubicin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - epirubicin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - epirubicin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epirubicin hydrochloride, quantity: 200 mg - injection, solution - excipient ingredients: sodium chloride; dilute hydrochloric acid; water for injections - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, and superficial bladder cancer (tis, ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).